<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938078</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-NBY-2016</org_study_id>
    <nct_id>NCT02938078</nct_id>
  </id_info>
  <brief_title>Ocular Comfort and Inflammation in Lid Hygiene Therapy</brief_title>
  <official_title>Ocular Comfort and Markers of Inflammation in Subjects Undergoing Lid Hygiene Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnesota Eye Consultants, P.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovaBay Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minnesota Eye Consultants, P.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days&#xD;
      and (2) the change in signs and symptoms of ocular surface disease in demodex-positive&#xD;
      subjects beginning the use of Avenova.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of subjects who have been diagnosed with bilateral demodex&#xD;
      blepharitis. Qualified symptomatic eyes will be randomized and monitored for 30 days; one eye&#xD;
      will undergo Avenova treatment twice daily and one eye will not undergo any study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">August 24, 2018</completion_date>
  <primary_completion_date type="Actual">August 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical parameters include prevalence of demodex mites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical exam parameters include prevalence of tear film break up time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical exam parameters include corneal and conjunctival staining.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical parameters include evaluation of meibomian gland including evaluation of lipid layer thickness..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation using tear osmolarity.</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical parameters include tear osmolarity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical parameters include tear ferning patterns.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Severity of Markers of Inflammation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical parameters include meibomian gland evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ocular Discomfort</measure>
    <time_frame>30 days</time_frame>
    <description>Change in ocular discomfort based on scores from Eyelid Inflammation questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ocular Discomfort</measure>
    <time_frame>30 days</time_frame>
    <description>Change in ocular discomfort based on scores from Ocular Surface Disease Index questionnaire. Scored on a scale of 0-100, with higher scores indicating greater disability.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Treatment Eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Treatment Eye</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Avenova Lid Cleanser</intervention_name>
    <description>Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.</description>
    <arm_group_label>Treatment Eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject signed and dated a IRB-approved informed consent document&#xD;
&#xD;
          -  Mild or greater Demodex (minimum 15 observable mites in six lashes)&#xD;
&#xD;
          -  Score of 20 or more on the OSDI Questionnaire&#xD;
&#xD;
          -  Score of 20 or more on the Eyelid Inflammation Questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in another prospective research study&#xD;
&#xD;
          -  Unable to attend two follow-up visits over 30 days&#xD;
&#xD;
          -  Current allergic conjunctivitis of the cornea, conjunctiva, or eyelid in either eye&#xD;
&#xD;
          -  Prior ocular trauma where surgery was indicated&#xD;
&#xD;
          -  Prior corneal transplant in either eye&#xD;
&#xD;
          -  Any ocular surgery within the past six months&#xD;
&#xD;
          -  Abnormal corneal scarring, erosions, or Stevens-Johnson syndrome&#xD;
&#xD;
          -  Anticipation of ocular surgery within the next 30 days&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Pregnant, nursing, or expect to become pregnant within the next 30 days&#xD;
&#xD;
          -  Known sensitivity to chlorine or Avenova&#xD;
&#xD;
          -  Moderate, or severe conjunctivochalasis&#xD;
&#xD;
          -  Contact lenses within the last 30 days and unwilling to discontinue for 30 days&#xD;
&#xD;
          -  Use of topical cyclosporine for less than 6 continuous months prior to baseline&#xD;
&#xD;
          -  Procedure such as pulsed light or commercial lid massage in last 30 days&#xD;
&#xD;
          -  Known history of autoimmune disease&#xD;
&#xD;
          -  Punctal plugs placed within the last 30 days&#xD;
&#xD;
          -  Use of Avenova or other lid cleansers within the last 30 days&#xD;
&#xD;
          -  Changes in systemic or ocular medications in the last 30 days&#xD;
&#xD;
          -  Unwilling to commit to the same ocular and systemic medications for 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad M Fahmy, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Eye Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minnesota eye Consultants, PA</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

